Formycon AG (FRA:FYB)

Market Cap	325.89M -25.0%
Revenue (ttm)	61.24M +18.3%
Net Income	-25.13M
EPS	-1.42
Shares Out	n/a
PE Ratio	n/a
Forward PE	166.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	18.34
Previous Close	19.04
Day's Range	18.34 - 19.58
52-Week Range	16.52 - 26.35
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 196
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: FYB

Financial Performance

In 2025, Formycon AG's revenue was 44.48 million, a decrease of -36.17% compared to the previous year's 69.67 million. Losses were -64.70 million, -48.52% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error